Induction Immunotherapy to Promote Immunologic Priming and Enhanced Response to Neoadjuvant Pembrolizumab + Chemotherapy in Triple Negative Breast Cancer (TNBC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs IRX 2 (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms NeoIRX

06 Jun 2023 Status changed to discontinued, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
06 Jun 2023 Results assessing preliminary outcomes of pembrolizumab in stage II/III triple-negative breast cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
23 Mar 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com